Serum leptin levels are associated with tamoxifen-induced hepatic steatosis


Günel N., Coşkun U., TÖRÜNER F. S., Sancak B., YILMAZ E., Cengiz O., ...Daha Fazla

Current Medical Research and Opinion, cilt.19, sa.1, ss.47-50, 2003 (Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 1
  • Basım Tarihi: 2003
  • Doi Numarası: 10.1185/030079902125001308
  • Dergi Adı: Current Medical Research and Opinion
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.47-50
  • Anahtar Kelimeler: breast cancer, hepatic steatosis, leptins, tamoxifen
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Purpose: Tamoxifen, used in breast cancer treatment, may induce hepatic steatosis. It has been suggested that leptin, which has a relationship with body fat stores, may be involved in the pathogenesis of hepatic steatosis. In this study, we compared serum leptin levels in tamoxifen-treated patients with and without hepatic steatosis. Methods: Thirty-four women with breast cancer receiving tamoxifen were included in the study. Serum samples were obtained from the patients before and 3 months after tamoxifen therapy. Results: Increased hepatic steatosis was detected in 15 of 34 (44%) patients after 3 months of tamoxifen therapy. Serum leptin levels were found to be significantly elevated in patients with increased hepatic steatosis (37.3 ± 17.7 to 50.5 ± 22.4 ng/ml, p = 0.023) compared to patients without or stable hepatic steatosis (48.2 ± 20.2 to 42.6 ± 14.9 ng/ml, p > 0.05) after tamoxifen treatment. Conclusion: Leptin may play a role in tamoxifen-induced hepatic steatosis. The exact mechanism involved should be investigated in further studies.